New FDA Approvals: FDA Approves First Abraxane Generic
-
Nov 14, 2024
Oct. 8: The FDA approved Sandoz Inc.’s paclitaxel for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. It is the first FDA-approved generic of Abraxane from Abraxis BioScience LLC, a division of Bristol Myers Squibb. The agent is available as a 100 mg single-dose vial of lyophilized powder. Recommended dosing is 260 mg/m2 via a 30-minute intravenous infusion every three weeks. Drugs.com lists the price of one 100 mg vial of Abraxane as more than $1,673. Read more© 2025 MMIT
